Non classé
Educational Booklets For Togas Pilot Studies Participants Are Now Available
Crafted with input from both patients and field experts, these booklets will undergo translation into national languages before distribution among ...
DiCE Supports MOs Training Opportunity
As an integral part of our commitment to patient care, we are pleased to inform you that DiCE will award two grants to DiCE Full members who are in...
Do You Dare to Think Differently about Cancer?
The Cancer Grand Challenges mission is “Uniting the World’s brightest minds against cancer’s toughest challenges”. Founded by CRUK (Cancer ...
Predictive Values of Blood-based RNA Signature for the FOLFIRINOX/FOLFOX Response in Advanced Pancreatic Cancer
Presently, no widely recognised or established biomarkers are specifically designed to predict the effectiveness of FOLFIRINOX/FOLFOX (chemotherape...
DIPLOMA Trial: Minimally Invasive Surgery is an Effective Treatment Option for Early-Stage Pancreatic Cancer
A notable study, DIPLOMA, led by Abu Hilal, M.D., Ph.D., of the Istituto Ospedaliero Fondazione Poliambulanza in Brescia, Italy, involved a large c...
ESMO Study Confirms Precision Oncology Remains Largely Inaccessible to European Cancer Patients
As a European umbrella organisation, DiCE is vocal in addressing the disparities associated with cancer patients’ access to precision medicin...
Primary and Updated Analyses for DESTINY-Gastric02 Study: Trastuzumab Deruxtecan Continues to Demonstrate Benefit in Metastatic Gastric and Gastro-oesophageal Cancer
Human Epidermal Growth receptor 2 (HER2) is a protein involved in normal cell growth, found in small amounts in almost all human cells, including s...
RWE Research in mCRC
In a recent article published in the Future Oncology, Patient Advocates and DiCE CEO Zorana Maravic explored and enhanced the understanding of the ...
Manifesto for a Healthier Europe
DiCE, together with the EU Health Coalition, urges future EU leaders to prioritise health and life sciences. Ahead of next year’s European el...
EU Commission Approval of Tibsovo® (Ivosidenib) in IDH1-mutated Cholangiocarcinoma
The European Commission approved the use of Tibsovo® (Ivosidenib) as monotherapy for the treatment of locally advanced or metastatic cholangiocarc...
- « Previous Page
- 1
- 2
- 3
- 4
- ...
- 7
- Next Page »
